DCCT/EDIC Study Published Results: 1990-1999

  • Barnie A, Cleary P, Genuth S, Martin C, Mayfield R, Tamborlane W, Wesche J, Shamoon H, and the EDIC Research Group. Epidemiology of Diabetes interventions and Complications (EDIC): Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial cohort.  Diabetes Care 1999, 22(1):99-111. PMCID:2745938.
  • Zinman B, Cleary P, O'Leary D, Orchard T, and the EDIC Research Group. The effect of intensive diabetes treatment on carotid artery wall thickness in the Epidemiology of Diabetes Interventions and Complications (EDIC).  Diabetes 1999, 48(2):383-390. PMCID:2622732.
  • Purnell JQ, Hokanson JE, Marcovina SM, Cleary PA, Steffes MW, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. JAMA 1998, 280(2):140-146. PMCID:2622729.
  • Sibley SD, Hokanson JE, Steffes MW, Purnell JQ, Marcovina SM, Cleary PA, Brunzell JD.  Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.  Diabetes Care 1999, 22(7):1165-70. PMCID:2635089.
  • Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary P, Lachin J, Genuth S. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type I diabetes: Relevance of glycated collagen products versus HbA1c as markers of diabetic complications. Diabetes 1999, 48(4):870-880. PMCID:2862597.
  • The DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT).  Diabetologia 1998, 41(4):416-423. PMCID:2635092.
  • The DCCT Research Group.  Effect of intensive therapy on residual Beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: A randomized, controlled trial.  Ann Intern Med 1998, 128(7):517-523. PMID:9518395.
  • The DCCT Research Group.  Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.  Arch Ophthalmol 1998, 116(7):874-886. PMID:9682700.
  • Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD.  Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. JAMA 1998, 280(2):140-146. PMCID:2622729.
  • The DCCT Research Group.  Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997, 46(11):1829-1839. PMID:9356033.
  • The DCCT Research Group.  Hypoglycemia in the Diabetes Control and Complications Trial.  Diabetes 1997, 46(2):271-286. PMID:9000705.
  • The DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial.  Diabetes 1996, 45(10):1289-1298. PMID:8826962.
  • The DCCT Research Group.  Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996, 276(17):1409-1415. PMID:8892716.
  • The DCCT Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996, 174(4):1343-1353. PMID:8623868.
  • The DCCT Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial.  Diabetes Care 1996, 19(3):195-203. PMID:8742561.
  • The DCCT Research Group. Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996, 124(4):379-388. PMID:8554246.
  • Leiter LA, and the DCCT Research Group. Use of bioelectrical  impedance  analysis  measurements  in  patients  with  diabetes. Am J Clin Nutr 1996, 64 (3 Suppl) 515S-518S. PMID:8780373.
  • Purnell J, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD. Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM: Results from follow-up in the Diabetes Control and Complications Trial. Diabetes 1995, 44(10):1218-1226. PMCID:2866034.
  • The DCCT Research Group.  Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial.  Ann Neurol 1995, 38(6):869-880. PMID:8526459.
  • The DCCT Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995, 18(11):1415-1427. PMID:8722064.
  • The DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995, 18(11):1468-1478. PMID:8722072.
  • The DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial.  Diabetes 1995, 44(8):968-983. PMID:7622004.
  • The DCCT Research Group.  Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.  Am J Cardiol 1995, 75(14):894-903. PMID:7732997.
  • The DCCT Research Group.  Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial.  Kid Int 1995, 47(6):1703-1720. PMID:7643540.
  • The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy.  Ann Intern Med 1995, 122(8):561-568. PMID:7887548.
  • Klein R, Moss S, and the DCCT Research Group.  A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy.  Arch Intern Med 1995, 155(7):745-754. PMID:7695463.
  • The DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995, 102(4):647-661. PMID:7724182.
  • The DCCT Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: The Diabetes Control and Complication Trial.  Arch Ophthalmol 1995, 113(1):36-51. PMID:7826293.
  • The DCCT Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial.  Diabetes Care 1995, 18(3):361-376. PMID:7555480.
  • Nathan DM.  Inferences and implications:  Do the DCCT results apply in NIDDM? Diabetes Care 1995; 18(2):251-257. PMID:7729307.
  • Nathan DM. Was it intensive therapy or glycemic control that worked in the DCCT? Clinical Diabetes 1995; 13:5-6.
  • The DCCT Research Group.  Psychological aspects of the DCCT. In The Technology of Diabetes Care: Converging Medical and Psychosocial Perspectives 1994, 122-139.
  • Leiter LA, Lukaski HC, Kenny DJ, Barnie A, Camelon K, Ferguson RS, MacLean S, Simkins S, Zinman B, Cleary PA, and the DCCT Research Group. The use of Bioelectrical Impedance Analysis (BIA) to estimate body composition in the Diabetes Control and Complications Trial (DCCT).  Int J Obes Relat Metab Disord 1994, 18(12):829-835. PMID:7894522.
  • Schmidt LE, Cox MS, Buzzard IM, Cleary PA, and the DCCT Research Group. Reproducibility of a comprehensive diet history in the Diabetes Control and Complications Trial. J Am Diet Assoc 1994, 94(12):1392-1397. PMID:7963189.
  • The DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994, 125(2):177-188. PMID:8040759.
  • The DCCT Research Group. A screening algorithm to identify clinically significant changes in neuropsychological functions in the Diabetes Control and Complications Trial. J Clin Exp Neuropsychol 1994, 16:303-316. PMID:8021316.
  • Delahanty LM, Balford BN. The Role of Diet Behaviors in Achieving Improved Glycemic Control in Intensively Treated Patients in the Diabetes Control and Complications Trial. Diabetes Care, 1993 16(11):1453-1458. PMID:8299434.
  • Siebert C, Clark CM. Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Control Clin Trials 1993, 14(1):30-44. PMID:8440093.
  • Ahern J, Grove N, Strand T, Wesche J, Seibert C, Brenneman AT, Tamborlane WV, and the DCCT Research Group. The impact of the trial coordinator in the Diabetes Control and Complications Trial.  Diabetes Educ 1993, 19(6):509-512. PMID:8156864.
  • Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall PM, Steffes MW, for the Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Glomerular filtration rate measurements in clinical trials. J Am Soc Nephrol 1993, 4(5):1159-1171. PMID:8305642.
  • Anderson EJ, Richardson M, Castle G, Cercone S, Delahanty L, Lyon R, Mueller D, Snetselaar L, and the DCCT Research Group. Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. J Am Diet Assoc 1993, 93(7):768-772. PMID:8320402.
  • Delahanty L, Simkins SW, CamelonK, and the DCCT Research Group.  Expanded role of the dietitian in the Diabetes Control and Complications Trial: Implications for clinical practice. J Am Diet Assoc 1993, 93(7):758-767. PMID:8320401.
  • The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986. PMID:8366922.
  • The DCCT Research Group.  Baseline analysis of renal function in the Diabetes Control and Complications Trial.  Kid Int 1993, 43(3):668-674. PMID:8455366.
  • The DCCT Research Group.  Lipid and lipoprotein levels in patients with IDDM: Diabetes Control and Complications Trial Experience. Diabetes Care 1992, 15(7):886-894. PMID:1516509.
  • Ryan CM, Adams KA, Heaton RK, Grant I, Jacobson AM, and the DCCT Research Group. Neurobehavioral assessment of medical patients in clinical trials: The DCCT Experience. In Mohr E and Brouwers P, editors, Handbook of Clinical Trials; The Neurobehavioral Approach. Amsterdam/Lisse: Swets and Zeitlinger 1991, 215-240.
  • The DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991, 90(4):450-459. PMID:2012085.
  • The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Update. Diabetes Care 1990, 13(4):427-433. PMID:2180661.

STATISTICAL METHODS

  • Lachin JM. Worst-rank score analysis with informatively missing observations in clinical trials.  Control Clin Trials 1999, 20(5):408-422. PMID:10503801.
  • Lachin JM. Group sequential monitoring of distribution-free analyses of repeated measures.  Stat Med 1997, 16(6):653-668. PMID:9131754.
  • Lachin JM. Distribution-free marginal analysis of repeated measures. Drug Information Journal 1996, 30(4):1017-1028.
  • Rosenberger WF, Lachin JM, Bain RP. Nonparametric test of stochastic ordering for multiple longitudinal measures. J Biopharm Stat 1995, 5(3):235-243. PMID:8580926.
  • Lachin JM. Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 1992, 11(9):1151-1170. PMID:1509217.
  • Knoke JD. Nonparametric analysis of covariance for comparing change in randomized studies with baseline values subject to error. Biometrics 1991, 47(2):523-533. PMID:1912259.
  • Wei LJ, Su JQ, Lachin JM. Interim analyses with repeated measurements in a sequential clinical trial.  Biometrika 1990, 77(2):359-364.
  • Lan KKG, Lachin JM. Implementation of group sequential logrank tests in a maximum duration trial.  Biometrics 1990, 46(3):759-770. PMID:2242413.